Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0015436031
Fri, 11.11.2022
CureVac
CureVac Presents Preliminary Data from Phase 1 Study Expansionof Oncology Candidate CV8102
Data confirm CV8102’s safety and ability to strongly mobilize the immune system against tumors
Final data of complete Phase 1 dose-escalation and expansion study expected in H1 2023
TÜBINGEN, Germany/ Boston, USA – November 11, 2022 - CureVac N.V. (Nasda [ … ]
Thu, 10.11.2022
CureVac
CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
TÜBINGEN, Germany/ BOSTON, USA – November 10, 2022 – CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financia [ … ]
Thu, 10.11.2022
CureVac
CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
TÜBINGEN, Germany/ BOSTON, USA – November 10, 2022 – CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financia [ … ]
Thu, 18.08.2022
CureVac
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studies
Phase 1 initiated for modified [ … ]
Thu, 18.08.2022
CureVac
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studies
Phase 1 initiated for modified [ … ]
Thu, 18.08.2022
CureVac
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Milestone demonstrates CureVac’s continued execution on comprehensive clinical program of second-generation vaccine candidates for in [ … ]
Thu, 18.08.2022
CureVac
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Milestone demonstrates CureVac’s continued execution on comprehensive clinical program of second-generation vaccine candidates for in [ … ]
Tue, 05.07.2022
CureVac
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
TÜBINGEN, Germany/ Boston, USA – July 5, 2022 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that it has moved to assert its intellectual propert [ … ]
Tue, 05.07.2022
CureVac
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
TÜBINGEN, Germany/ Boston, USA – July 5, 2022 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that it has moved to assert its intellectual propert [ … ]
Wed, 22.06.2022
CureVac
CureVac Announces Voting Results of General Meeting
TÜBINGEN, Germany / BOSTON, USA – June 22, 2022 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual genera [ … ]